LXRX
LEXICON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.05
+0.74%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.04
From 52W high−22.35%
Volume7.43M
Market cap$912.16M
P/E (TTM)—
P/S (TTM)22.0x
Div yield—
Key dataSep 18, 2026
Open
$2.04
From 52W high
−22.35%
Volume
7.43M
Market cap
$912.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.9x
P/E (TTM)
—
RSI (14)
34.5
MomentumView details →
1D Return
+0.74%
YTD Return
+73.48%
SummaryUpdated Jun 1, 2026
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company founded in 1995 and headquartered in The Woodlands, Texas. The company went public in 2000 and focuses on discovering, developing, and commercializing small molecule pharmaceutical products primarily for cardiovascular, metabolic, and neurological conditions. Lexicon has evolved from a drug discovery company into a commercial-stage biopharmaceutical company with one approved product and multiple late-stage pipeline candidates targeting significant unmet medical needs.
Similar companies
Latest newsMore news →
Lexicon Pharmaceuticals earned a $10 million milestone payment from Novo Nordisk after achieving a key Phase 1 development milestone for LX9851, an oral non-incretin obesity candidate being developed by Novo Nordisk.27d agoLexicon Pharmaceuticals completed enrollment in its Phase III SONATA-HCM trial.45d ago